Moneycontrol
SENSEX NIFTY
YOU ARE HERE > MONEYCONTROL > MARKETS > PHARMACEUTICALS > News - Lupin

Lupin

BSE: 500257|NSE: LUPIN|ISIN: INE326A01037|SECTOR: Pharmaceuticals
SET ALERT
|
ADD TO PORTFOLIO
|
WATCHLIST
LIVE
BSE
Feb 16, 16:00
824.40
2.25 (0.27%)
VOLUME 126,944
LIVE
NSE
Feb 16, 15:59
825.10
2.8 (0.34%)
VOLUME 589,728
News on Lupin
Select Year: 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2000-2005
Lupin gains 3% on launch of generic Tamiflu capsules in US market 

2.19 pm | 12 Feb 2018 |  Source: Moneycontrol.com

The company announced the launch of its Oseltamivir Phosphate Capsules, USP having received an approval from the United States Food and Drug Administr...

Lupin launches generic Tamiflu in US

2.11 pm | 12 Feb 2018 |  Source: Moneycontrol.com

Pharma major Lupin announced the launch of its Oseltamivir Phosphate Capsules, USP having received an approval from the United States Food and Drug Ad...

Lupin launches generic Kapvay tablets in US

3.02 pm | 08 Feb 2018 |  Source: Moneycontrol.com

Lupin announced the launch of its Clonidine Hydrochloride extended-release tablets, 0.1mg, having received an approval from the United States Food and...

Lupin JV announces outcome of Phase III study for biosimilar, Etanercept

12.32 pm | 07 Feb 2018 |  Source: Moneycontrol.com

L Biologics (YLB) announced that a global Phase III clinical trial of its investigational Etanercept biosimilar (YLB113) has met with successful outco...

Lupin JV announces outcome of Phase III study for biosimilar, Etanercept

12.32 pm | 07 Feb 2018 |  Source: Moneycontrol.com

L Biologics (YLB) announced that a global Phase III clinical trial of its investigational Etanercept biosimilar (YLB113) has met with successful outco...

Rakesh Jhunjhunwala owned stock reports 65% drop in PAT; CLSA cuts target price on Lupin 

8.22 am | 07 Feb 2018 |  Source: Moneycontrol.com

The company's revenues dropped 11.3 percent on year-on-year (YoY) basis Rs 3975.7 crore in the third quarter....

Lupin hopes to resolve warning letter on Goa and Indore plants by end of FY19

8.07 pm | 06 Feb 2018 |  Source: Moneycontrol.com

Lupin was hit by a warning letter from USFDA for its manufacturing plants in Goa and Pithampur Unit II (Indore) in November last year....

News highlights of the day: Why should I quit BJP, let the party throw me out, says Yashwant Sinha

7.00 pm | 06 Feb 2018 |  Source: Moneycontrol.com

This blog will keep track of key global and local developments impacting business and markets through the day. Important local and global political de...

Lupin net profit drops 65% on sliding US biz and forex loss

4.37 pm | 06 Feb 2018 |  Source: Moneycontrol.com

The foreign exchange loss stood at Rs. 82.1 crore and the company also took a one-time charge of 36 crore related to changes in tax rate in US from 35...

Lupin Q3 disappoints, profit tanks 65% to Rs 222 cr; margin contracts sharply 

2.59 pm | 06 Feb 2018 |  Source: Moneycontrol.com

Operating profit at Rs 689 crore (down 43.5 percent YoY) and margin at 17.3 percent (contracted 990 basis points YoY) were far lower than analyst esti...

Lupin Q3 profit seen down 33% to Rs 427 cr on pricing pressure in US 

2.26 pm | 06 Feb 2018 |  Source: CNBC-TV18

Analysts expect US revenue to decline 30-35 percent YoY in Q3FY18 while India should continue recovering post GST....

Lupin gets USFDA nod to market its skin conditions cream

6.00 pm | 01 Feb 2018 |  Source: PTI

The company has received final approval to market its generic Clobetasol Propionate cream USP, 0.05 per cent, from the United States Food and Drug Adm...

Lupin to consider December quarter results on February 6, 2018

9.42 am | 24 Jan 2018 |  Source: Moneycontrol.com

A meeting of the Board of Directors of the Company will be held on Tuesday, February 6, 2018, at Mumbai, inter alia, to consider and take on record un...

Lupin forays into OTC segment;eyes Rs 300 cr turnover in 5 years

3.36 pm | 15 Jan 2018 |  Source: PTI

The Mumbai-based firm has introduced its legacy product 'Softovac' across the country as an OTC medicine....

Lupin eyes $54-billion complex generics market in US to fight intense competition

10.16 am | 11 Jan 2018 |  Source: Moneycontrol.com

Move comes as the drugmaker looks to insulate itself from pricing pressure and intense competition....

Lupin receives FDA approval for generic Tamiflu capsules

3.49 pm | 10 Jan 2018 |  Source: Moneycontrol.com

Lupin has received final USFDA approval for Oseltamivir Phosphate Capsules USP, 30 mg (base), 45 mg (base), and 75 mg (base) to market a generic versi...

Stocks in the news: Infosys, GAIL, Apollo Tyres, SAIL, Rel Infra, Motherson, Axis Bank 

8.06 am | 10 Jan 2018 |  Source: Moneycontrol.com

Infosys | Gail | Electrosteel Castings | Balasore Alloys | NMDC | SAIL | Bhushan Steel | Whirlpool | Syndicate Bank | BoB | Union Bank | IL...

Buy Lupin; target of Rs 1140: JM Financial

4.14 pm | 13 Nov 2017 |  Source: Moneycontrol.com

JM Financial is bullish on Lupin has recommended buy rating on the stock with a target price of Rs 1140 in its research report dated October 31, 2017....

Hold Lupin; target of Rs 1050: Sharekhan

11.17 am | 09 Nov 2017 |  Source: Moneycontrol.com

Sharekhan recommended hold rating on Lupin with a target price of Rs 1050 in its research report dated October 30, 2017....

Hold Lupin; target of Rs 1030: Reliance Securities

4.56 pm | 06 Nov 2017 |  Source: Moneycontrol.com

Reliance Securities recommended hold rating on Lupin with a target price of Rs 1030 in its research report dated October 31, 2017....

1 2 3 4
Quick Links for Lupin
Explore Moneycontrol
Stocks     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | Others
Mutual Funds     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.